Its about Time !! Here comes Europe !!! $$$VIVO Cannabis Partners with Linneo Health to Supply Medical Cannabis in Europe Tuesday, September 17, 2019, 7:00 AM ET Linneo Health Receives EU-GMP Certification NAPANEE, ON, Sept. 17, 2019 /CNW/ - VIVO Cannabis Inc. (TSX-V: VIVO, OTCQX: VVCIF) ("VIVO" or the "Company") today announced it has partnered with Linneo Health S.L. ("Linneo Health"), a subsidiary of Alcaliber S.A., to be its European medical cannabis supply partner. Linneo Health, a European leader in the pharmaceutical cannabis industry, recently received its EU-GMP (Good Manufacturing Practices) certification from the Spanish regulatory authorities. The agreement is a multi-year commitment, with increasing supply volumes as VIVO expands in the European medical market. "Our partnership with Linneo Health is part of our strategic priority to accelerate international market growth," said Barry Fishman, Chief Executive Officer of VIVO. "We are excited to have an EU-GMP certified source of medical cannabis located within Europe. Through this partnership, we expect to be able to supply the European high-growth market with premium medical cannabis products and services. Our European based supply will allow VIVO to contribute to addressing the unmet medical needs of patients in Germany, which is one of our key target markets for international expansion." In late March 2019, VIVO's German subsidiary, ABcann Germany GmbH ("ABcann Germany"), was granted its pharmaceutical wholesale license and GDP-certificate by the responsible authorities of the state of Brandenburg. VIVO is now pursuing narcotic and import license applications in Germany to facilitate imports from other non-EU countries, including Canada, and expects to have its first products sold in the German market in early 2020. In early February 2019, VIVO exported three of its proprietary cultivars, covering a broad range of cannabinoid profiles, to Linneo Health in Spain. These cultivars were propagated to form VIVO's genetic basis for commercial cultivation in Europe. The agreement between ABcann Germany and Linneo Health is part of a long-term growth strategy of cooperation, the first step of which is the cultivation of EU-GMP certified cannabis, and represents the foundation on which VIVO and Linneo Health intend to complete the regulatory work required for the launch of medical cannabis in Europe, using a focused and phased approach. "This agreement with VIVO Cannabis is a significant milestone for Linneo Health, as it strengthens our presence in international markets, consolidates our position as the partner of choice for the pharmaceutical industry, and will help us bring top quality cannabis products to patients in need," said Jos Antonio de la Puente, Chief Executive Officer of Linneo Health.